Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Clin Exp Rheumatol ; 38(5): 1001-1007, 2020.
Article in English | MEDLINE | ID: mdl-32359034

ABSTRACT

The main aim of this systematic literature review (SLR) was to summarise the evidence in the use of biological therapies in calcium pyrophosphate deposition disease (CPPD). We performed a SLR using PubMed, Embase and Cochrane databases. Only studies reporting the efficacy of biologics in CPPD were selected. The search resulted in 83 articles; 11 were further evaluated in the SLR. Seventy-six patients were included: 2 received infliximab, whereas 74 anakinra. Anakinra was used in refractory disease (85.1%) or in patients with contraindications to standard treatments (23.0%). Clinical response to anakinra was observed in 80.6% of patients with acute and 42.9% of those with chronic CPPD. Short-term treatment was well tolerated and adverse events were reported in 4.1% of the cases. This review provides evidence in favour of the use of anakinra as a therapeutic option in patients with CPPD, especially in acute refractory CPPD or when standard treatments are contraindicated.


Subject(s)
Biological Products , Chondrocalcinosis , Biological Products/adverse effects , Calcium Pyrophosphate , Chondrocalcinosis/diagnosis , Chondrocalcinosis/drug therapy , Humans , Infliximab , Interleukin 1 Receptor Antagonist Protein/adverse effects
2.
Clin Exp Rheumatol ; 38(3): 472-478, 2020.
Article in English | MEDLINE | ID: mdl-31573476

ABSTRACT

OBJECTIVES: To explore the prevalence of the ultrasound (US) findings of enthesitis in a group of healthy subjects. METHODS: US assessments of quadriceps, patellar and Achilles tendons, and plantar fascia entheses were performed by a rheumatologist on 82 healthy volunteers focusing on the US findings indicative of "active" inflammation according to the Outcome Measures in Rheumatology (OMERACT) definitions. RESULTS: Eight hundred and twenty entheses were evaluated in 82 healthy subjects. One or more US findings of "active" inflammation were found in at least one enthesis in 30 out of 82 subjects (34.1%), in 69 out of 820 entheses (8.4%). Entheseal thickening, hypoechogenicity and PD signal were respectively found in at least one enthesis in 23 (28.0%), 11 (13.4%) and 8 (9.8%) out of 82 subjects. Among the 69 entheses showing US features of "active" inflammation, entheseal thickening, hypoechogenicity and PD signal were found as isolated in 61 entheses and in combination in the remaining 8 (entheseal thickening and hypoechogenicity). CONCLUSIONS: Our results show a relatively high prevalence of US findings of "active" inflammation at the lower limb entheses in a group of healthy subjects, thus questioning the discriminant power of the OMERACT definitions for the diagnosis of "active" enthesitis. A combination of grey-scale and PD findings at a specific threshold to be defined could improve both the reliability and clinical usefulness of US.


Subject(s)
Arthritis/diagnostic imaging , Enthesopathy/diagnostic imaging , Ultrasonography , Healthy Volunteers , Humans , Lower Extremity/physiopathology , Prevalence , Reproducibility of Results , Severity of Illness Index
SELECTION OF CITATIONS
SEARCH DETAIL